Form 4: BioXcel Therapeutics Chief Scientific Officer Granted Stock Options

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted options to purchase 270,000 shares of common stock.

Summary

• Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, was granted stock options on January 7, 2025.
• The options allow him to purchase 270,000 shares of common stock at an exercise price of $0.4713 per share.
• These options vest in twelve equal monthly installments over a twelve-month period, contingent on his continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule encourages continued employment and contribution to the company's success.

Risks

• The value of the options is dependent on the future performance of BioXcel Therapeutics' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the recipient.

Future Outlook

The vesting of the stock options is contingent on the continued employment of Frank Yocca with BioXcel Therapeutics.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize key personnel.
• The vesting schedule of 12 months is fairly typical for executive stock options.
• The exercise price of $0.4713 is specific to BioXcel Therapeutics' stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to contribute to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, BioXcel Therapeutics, executive compensation, insider trading, BTAI, Frank Yocca, equity